Clinical Trial 51352

Phoenix, AZ 85013


The Ivy Brain Tumor Center at Barrow Neurological Institute is conducting a Phase 2 study of sonodynamic therapy (SDT) in patients with recurrent glioblastoma (rGBM).

The primary objectives of this nonsurgical study are to evaluate the safety and preliminary efficacy of SDT using SONALA-001 (ALA) and Exablate Type-2 device in patients with recurrent or progressive GBM.

Oral ALA is a drug currently used in patients with certain types of tumors to assist in tumor visualization and increase the amount of tumor resected during surgery. In this study, we will investigate the drug’s ability to make the tumor tissue more sensitive to ultrasound, ultimately slowing tumor growth.


  • You are 18 years or older.
  • You have a histologically diagnosed primary glioblastoma that has recurred or progressed, and resection is not indicated.
  • You received previous first-line treatment with standard-of-care radiotherapy and temozolomide. Temozolomide is only required if the tumor has at least partial methylation of the MGMT promoter.

Available At:

Ivy Brain Tumor Center at Barrow Neurological Institute
2910 North Third Avenue
Phoenix, AZ 85013
View Clinic Location


If you or someone you care for is interested in participating and lives within 50 miles of the location shown, please complete the form below and click 'Submit'

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.